Pluristem Therapeutics, Inc. (PSTI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.55-0.05 (-3.13%)
At close: 4:00 PM EDT
People also watch:
CUROPXAOSIRATHXCYTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.60
Prev Close1.60
Bid1.55 x 45800
Ask1.79 x 1000
Day's Range1.55 - 1.60
52wk Range0.71 - 1.86
1y Target EstN/A
Market Cap125.12M
P/E Ratio (ttm)-5.31
Beta0.20
Volume146,605
Avg Vol (3m)153,878
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Pluristem Therapeutics, Inc. is trading above its 50 day moving average : PSTI-US : September 28, 2016
    Capital Cube2 days ago

    Pluristem Therapeutics, Inc. is trading above its 50 day moving average : PSTI-US : September 28, 2016

    Categories: Europe Stock Alerts Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pluristem Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Accesswire7 days ago

    Pluristem Therapeutics, Inc. - "Biotech Nation"

    NEW YORK, NY / ACCESSWIRE / September 22, 2016 / Pluristem Therapeutics, Inc.'s (NASDAQ CM: PSTI, TASE: PSTI) President and COO, Yaky Yanay, published an editorial piece in The Jerusalem Post, which has ...

  • Pluristem Therapeutics Inc. (PSTI) Gears Up For Critical Blood Stem Cell Trial
    Insider Monkey10 days ago

    Pluristem Therapeutics Inc. (PSTI) Gears Up For Critical Blood Stem Cell Trial

    Investors who play the developing biotech niche are always on the lookout for shortcuts to approval. A shortcut can come in two ways. First, they can be regulatory and explicit, as in fast track status, orphan designations, accelerated approval pathways and the like. Second, they can be implicit due to the nature of the medical technology […]